system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: OBJECTIVE, METHODS, RESULTS. Meshes: Acetylcholine, Aged, Arginase, Arginine, Cardiovascular Agents, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Endothelium, Vascular, Enzyme Inhibitors, Female, Humans, Laser-Doppler Flowmetry, Male, Microvessels, Middle Aged, Nitroprusside, Ornithine, Peripheral Vascular Diseases, Severity of Illness Index, Vascular Resistance, Vasodilation, Vasodilator Agents.
user
Does arginase Inhibition improve Microvascular Endothelial Function in Patients With Type 2 Diabetes Mellitus? Context: The development of microvascular complications in diabetes is a complex process in which endothelial dysfunction is important. Emerging evidence suggests that arginase is a key mediator of endothelial dysfunction in type 2 diabetes mellitus by reciprocally regulating nitric oxide bioavailability. The aim of this prospective intervention study was to test the hypothesis that arginase activity is increased and that arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes and microvascular dysfunction. Microvascular endothelium-dependent and -independent dilatation was determined in patients with type 2 diabetes (n = 12) and healthy age-matched control subjects (n = 12) with laser Doppler flowmetry during iontophoretic application of acetylcholine and sodium nitroprusside, respectively, before and after administration of the arginase inhibitor N Microvascular endothelium-dependent dilatation was impaired in subjects with type 2 diabetes (P < .05). After administration of N
assistant
Arginase inhibition improves microvascular endothelial function in patients with type 2 diabetes and microvascular dysfunction. Arginase inhibition may represent a novel therapeutic strategy to improve microvascular endothelial function in patients with type 2 diabetes. Final Decision: yes